Download the Complete Report Here

By Brandon Hornback

Aurora Cannabis Inc. (NASDAQ: ACB) smoked another quarter, led by top-line growth, profitability, and disciplined capital allocation. And in fresh news, there’s positive cash flow right around the corner.

Take a hit off this: The top line increased 11%, driven primarily by strong medical cannabis performance linked to high demand from Germany, Poland, and Australia. Gross margin expanded significantly to 61%, led by the medical business, which continues to outperform the broader cannabis industry.

Management expects a return to positive free cash flow in its fiscal third quarter, which ends in December. Additionally, ACB maintains a rock-solid balance sheet with C$142 million in cash, and no cannabis-related debt.

To top it off, the re-certification of Aurora’s EU-GMP and Leuna facility expansion has placed Aurora among a short list of cannabis companies, offering visibility for sustainable growth and margin improvement.

Turning to valuation, ACB is trading at 0.9x forward sales and 6.5x EV/EBITDA, below peer averages even amid an attractive industry positioning. For investors interested in a straightforward play on medical and international cannabis markets, ACB is a name to keep on the shelf.

Download the full report to learn more about Aurora’s transformation from turnaround story to trailblazer.

Download the Complete Report Here

Read Exec Edge’s Initiation on Aurora Here

Subscribe to our Weekly Newsletter to Receive All Research

Contact:

Executives-Edge.com

Rayk@capmarketsmedia.com